New York Stock Exchange-listed business process outsourcing major Genpact Ltd has appointed Hanspeter Spek as a member of its board, according to a statement. Presently, Spek serves as the chairman of the board of Germany-based Sanofi SA and most recently worked as president of Global Operations at the pharmaceutical giant prior to his retirement in June 2013.
“With his extensive global experience, he will bring significant value to Genpact and its board,” Robert Scott, chairman of the board at Genpact, said.
Spek started his career with Pfizer where he worked for over 10 years in product and marketing management roles. Thereafter in 1985, he joined Sanofi where he held several management positions, including senior vice president of Europe region following the merger with Synthélabo in 1999, director of worldwide operations of Sanofi-Synthélabo, and executive vice president of global pharmaceutical operations for Sanofi-Aventis before he was promoted to president of global operations in 2009.
“Genpact is thrilled to add another outstanding business leader to our board. Hanspeter, who has had such a long and distinguished career in the pharmaceutical and life sciences industry, will bring great insights in one of our core focus industries,” NV ‘Tiger’ Tyagarajan, president and CEO, Genpact, said.
Spek has also been non-executive director of Zentiva AS (Prague) and Zentiva N.V. Besides, he is director of Chattem Inc and a member of supervisory board of Celesio AG.
Graduated from a business school in Germany, Spek completed a management training programme at Pfizer International.
With global operations in 24 countries around the world, Genpact was started in 1997 as a business unit within General Electric. In 2005, it was spun off from GE and went public on the NYSE in August 2007.
(Edited by Joby Puthuparampil Johnson)
